Economic evaluations of oral medications for breast cancer treatment in the U.S.: a systematic review with a focus on cost-effectiveness threshold

References

• Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer. 2014;21(3):R235–46.
   PubMed Web of Science ®Google Scholar
• Carrington C. Oral targeted therapy for cancer. Aust Prescr. 2015;38(5):171–176.
   PubMed Web of Science ®Google Scholar
• Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Discov Med. 2013;15(83):231–241.
   PubMed Web of Science ®Google Scholar
• Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA-Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Nounou MI, ElAmrawy F, Ahmed N, et al. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl). 2015;9(Suppl 2):17–34.
   PubMedGoogle Scholar
• Shih YT, Xu Y, Liu L, et al. Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries. J Clin Oncol. 2017;35(22):2482–2489.
   PubMed Web of Science ®Google Scholar
• Jakka S, Rossbach M. An economic perspective on personalized medicine. Hugo J. 2013;7(1):1.
   Google Scholar
• Truven Health Analytics. Red book online. [cited 2019 Jul 16]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook
   Google Scholar
• Mistry R, May JR, Suri G, et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer: a U.S. payer perspective. J Manag Care Spec Pharm. 2018;24(6):514–523.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Steensma D, Sanjuan JR, et al. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10(4):e208–11.
   PubMedGoogle Scholar
• Zafar SY. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst. 2016;108(5):djv370.
   PubMedGoogle Scholar
• Santos AS, Guerra-Junior AA, Godman B, et al. Cost-effectiveness thresholds: methods for setting and examples from around the world. Expert Rev Pharmacoecon Outcomes Res. 2018;18(3):277–288.
   PubMed Web of Science ®Google Scholar
• Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13(10):716–717.
   PubMed Web of Science ®Google Scholar
• Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27(1):71–76.
   PubMed Web of Science ®Google Scholar
• Takeda AL, Jones J, Loveman E, et al. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health Technol Assess. 2007;11(19):1–62.
   Web of Science ®Google Scholar
• Jones L, Hawkins N, Westwood M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol Assess. 2004;8(5):1–143.
   Web of Science ®Google Scholar
• Ward S, Simpson E, Davis S, et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(40):1–144.
   Web of Science ®Google Scholar
• Annemans L. Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making. Pharmacoeconomics. 2008;26(5):409–423.
   PubMed Web of Science ®Google Scholar
• Benedict A, Brown RE. Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer. Expert Opin Pharmacother. 2005;6(11):1789–1801.
   PubMed Web of Science ®Google Scholar
• Frederix GW, Severens JL, Hovels AM, et al. Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes. Value Health. 2012;15(1):94–105.
   PubMed Web of Science ®Google Scholar
• John-Baptiste AA, Wu W, Rochon P, et al. A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. PLoS One. 2013;8(5):e62614.
   PubMed Web of Science ®Google Scholar
• PRISMA Group, Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA-J Am Med Assoc. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61.
   PubMedGoogle Scholar
• Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Res Treat. 1993;25(2):97–105.
   PubMed Web of Science ®Google Scholar
• Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer. 2004;101(6):1311–1322.
   PubMed Web of Science ®Google Scholar
• Verma S, Maraninchi D, O’Shaughnessy J, et al. Capecitabine plus docetaxel combination therapy. Cancer. 2005;103(12):2455–2465.
   PubMed Web of Science ®Google Scholar
• Reed SD, Li Y, Anstrom KJ, et al. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2009;27(13):2185–2191.
   PubMed Web of Science ®Google Scholar
• Lipsitz M, Delea TE, Guo A. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. Curr Med Res Opin. 2010;26(10):2315–2328.
   PubMed Web of Science ®Google Scholar
• Lopes G, Gluck S, Avancha K, et al. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat. 2013;137(1):187–193.
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Ali AA, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016;160(1):187–196.
   PubMed Web of Science ®Google Scholar
• Locker GY, Mansel R, Cella D, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007;106(2):229–238.
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Zeichner SB, et al. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2014;147(2):433–441.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer. 2001;91(3):484–489.
   PubMed Web of Science ®Google Scholar
• Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer. 2009;115(3):489–498.
   PubMed Web of Science ®Google Scholar
• Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2019;175(3):775–779.
   PubMed Web of Science ®Google Scholar
• Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast Cancer Res Treat. 2016;159(3):565–573.
   PubMed Web of Science ®Google Scholar
• Simons WR, Jones D, Buzdar A. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther. 2003;25(11):2972–2987.
   PubMed Web of Science ®Google Scholar
• Thompson MF, Chen L, Tangirala M, et al. Cost-effectiveness of docetaxel-cyclophosphamide versus doxorubicin-cyclophosphamide for breast cancer. Am J Pharm Benefits. 2011;3(5):276–283.
   Google Scholar
• Delea TE, Karnon J, Smith RE, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care. 2006;12(7):374–386.
   PubMed Web of Science ®Google Scholar
• Delea TE, Karnon J, Sofrygin O, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer. 2007;7(8):608–618.
   PubMed Web of Science ®Google Scholar
• Mamiya H, Tahara RK, Tolaney SM, et al. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Ann Oncol. 2017;28(8):1825–1831.
   PubMed Web of Science ®Google Scholar
• Thompson D, Taylor DC, Montoya EL, et al. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health. 2007;10(5):367–376.
   PubMed Web of Science ®Google Scholar
• Delea TE, Taneja C, Sofrygin O, et al. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. Clin Breast Cancer. 2010;10(4):267–274.
   PubMed Web of Science ®Google Scholar
• Xie J, Hao Y, Zhou ZY, et al. Economic evaluations of everolimus versus other hormonal therapies in the treatment of HR+/HER2- advanced breast cancer from a US payer perspective. Clin Breast Cancer. 2015;15(5):e263–76.
   PubMedGoogle Scholar
• Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol. 1993;11(4):771–776.
   PubMed Web of Science ®Google Scholar
• Naeim A, Keeler EB. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?. Crit Rev Oncol Hematol. 2005;53(1):81–89.
   PubMed Web of Science ®Google Scholar
• Le QA. Structural uncertainty of Markov models for advanced breast cancer: a simulation study of lapatinib. Med Decis Making. 2016;36(5):629–640.
   PubMed Web of Science ®Google Scholar
• Woods B, Sideris E, Palmer S, et al. NICE DSU Technical Support Document 19: Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. Sheffield, UK 2017.
   Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Med Decis Making. 2012;32(5):690–700.
   PubMed Web of Science ®Google Scholar
• Society AC. Survival rates for breast cancer . 2019 [cited 2019 Jul 16]. Available from: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
   Google Scholar
• Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332(7543):699–703.
   PubMed Web of Science ®Google Scholar
• Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–1170.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology for breast cancer: version 3.2019. [cited 2019 Sep 16]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar